Natco Pharma Ltd

Natco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multiple myeloma, in the US. The company has launched 2.5 mg, and 20 mg strengths of the generic version of Revlimid (lenalidomide capsules) through its marketing partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, Natco Pharma said in a regulatory filing. "With this launch the companies (have) made available all the strengths of lenalidomide in the US market," it added. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma, the filing said.

The drug major filed an abbreviated new drug application (ANDA) for generic versions of Olaparib tablets - 100 mg and 150 mg with the US Food and Drug Administration (USFDA)

Its consolidated revenue from operations during the quarter under review stood at Rs 884.6 crore compared to Rs 410.3 crore in the same period last fiscal, it added.

In the past three months, Natco Pharma has outperformed the market by gaining 8 per cent, as compared to 8 per cent decline in the S&P BSE Sensex.

Natco Pharma Ltd on Thursday said it has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupiravir capsules 200 mg for treatment of COVID-19. MPP had taken licence from Merck Sharp & Dohme Corp (MSD), USA for the same, the company said in a statement. Natco said with this licence agreement it can manufacture and sell Molnupiravir capsules 200 mg for Indian market, which will be sold under brand name MOLNUNAT for treatment of COVID-19 infection in patients who have high risk of progression of the disease including hospitalisation or death. It further said, "This agreement allows Natco to expand access to COVID-19 medicines in 105 countries in generic name. Under the licence, Natco can set its own price for the generic products it produces, paying a royalty on sales to MSD," the company said in a regulatory filing. However, MSD, Ridgeback Biotherapeutics and Emory University will not receive royalties for sales of

Below 14,416, Nifty could slide towards next support of 14,150

Out of these 344 stocks, 211 stocks are trading with a positive crossover. This scenario indicates that over 50 per cent stocks are signalling positive bias.

Lenalidomide drug is used to treat various types of cancers by slowing or stopping the growth of aberrant cells

Natco is also awaiting regulatory approval for a product based on CTPR, which is a broad spectrum insecticide used in several crops

At a time when the pharmaceutical industry in the State are complaining lack of government support in the State, Hyderabad-based Natco Pharma is planning to expand its Active Pharmaceutical Ingredient (API) and intermediates manufacturing facility and R&D in Tamil Nadu. The company is looking at investing in its existing facility, in Thiruvallur District.The company would be investing around Rs 100 crore in addition to the existing investmenbt of Rs 86.82 crore in the facility to manufacture 16 campaign products at a time, out of 42 API products and R&D activity, with a production capacity of 66.32 tonnes per annum from existing production capacity of 46.267 tonnes per annum. The proposed expansion is in a total land of 10.57 hectre in possession of the company.According to an environmental impact assessment report submitted in connection with the expansion plan, the expansion is in order to meet the growing market demand for pharmceutical products in the country.The proposed .

Project is expected to employ 1,200 persons directly and 300 persons indirectly after the expansion

Clearance is subject to compliance of certain conditions; Project expected to create 1,500 jobs

Shares of Natco Pharma were trading 1.52 per cent up at Rs 909 on BSE

Revenue and profit growth was driven by the surge in formulation business, according to Natco

Hyderabad-based Natco Pharma Limited has reported a 69.7 per cent jump in its consolidated net profit at Rs 47.6 crore for the quarter ended June, on the back of an increase in revenue from formulations. The company's net profit was Rs 28.07 crore in the corresponding period last year.

The total income from operations in this 4th quarter doubled at Rs 406.97 cr from Rs 200.8 cr in the year ago period